Moderna Inc.
Moderna Reports 2023 Financial Results and Provides Business Update
Summary
Moderna, Inc. announced preliminary financial results for the fiscal year ended December 31, 2023, reporting approximately $6.7 billion in product sales. The company also disclosed that its cash, cash equivalents, and investments exceeded $13 billion as of the year-end. Moderna provided an outlook for 2024, expecting $4 billion in product sales and anticipating a return to sales growth in 2025. The company also highlighted significant progress in its pipeline, with nine late-stage programs having anticipated milestones in 2024 and 2025.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement